Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.

Introduction: Head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin-based chemoradiation often suffer from cisplatin-induced hearing loss (CIHL). To prevent toxicities, patients receive hydration before and after cisplatin infusions. This study evaluated cisplatin-induced hearing loss between a long and short duration of infusion and volume of hydration schedule (DIVHS).

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Introduction: Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequently experience irreversible sensorineural hearing loss (SNHL). Patients with low lumbar skeletal muscle index (LSMI) may experience higher serum peak dosages of cisplatin. This study investigated whether pre-treatment low LSMI is associated with increased SNHL upon cisplatin-based CRT.

Diagnostic value of preoperative measures in selecting post-lingually deafened candidates for cochlear implantation - a different approach.

Objectives: We examined which preoperative diagnostic measure is most suited to serve as a selection criterion to determine adult cochlear implantation (CI) candidacy.

Design: Preoperative diagnostic measures included pure tone audiometry (PTA; 0.5, 1, 2, 4 kHz), speech perception tests (SPT) unaided with headphones and with best-aided hearing aids (in quiet and in noise).